Witkoff bashes ‘treasonous' leak of US intel assessment of Iran strikes
Steve Witkoff, President Trump's top envoy to the Middle East, blasted what he called 'treasonous' leaking of information after multiple media outlets reported that the administration's strikes on Iran only set its nuclear program back a few months.
'Well, it goes without saying that leaking that type of information, whatever the information, whatever side it comes out on, is outrageous,' Steve Witkoff told Fox News's 'The Ingraham Angle' Tuesday night. 'It's treasonous.'
'So it ought to be investigated and whoever did it, whoever is responsible for it should have been — should be held accountable,' Witkoff said. 'It could hurt lives in the future. There is — leaking is a completely unacceptable thing.'
CNN, The New York Times and other news outlets reported Tuesday that an internal government report found strikes on the three facilities over the weekend delayed Iran's nuclear program by only a few months, despite initial assertions from Trump administration officials that those sites had been destroyed.
The report also said Iran had moved much of its enriched uranium before the strikes, according to multiple outlets.
Defense Secretary Pete Hegseth said Wednesday at the NATO summit in the Netherlands that a leak investigation was underway, while Trump blasted the news outlets that reported on the internal assessment as 'scum.'
Trump and other top officials have been adamant that the nuclear facilities were 'obliterated,' even as experts have said it would take days to determine the extent of the damage.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
36 minutes ago
- Los Angeles Times
Court orders Trump administration to facilitate another deported man's return from El Salvador
WASHINGTON — A federal appeals court in New York on Tuesday ordered the Trump administration to facilitate the return of a man who was deported to El Salvador roughly 30 minutes after the court suspended an order to remove him from the U.S. The ruling in Jordin Alexander Melgar-Salmeron's case marks at least the fourth time this year that President Trump's administration has been ordered to facilitate the return of somebody mistakenly deported. The government said 'a confluence of administrative errors' led to Melgar-Salmeron's deportation on May 8, according to the decision by a three-judge panel from the 2nd U.S. Circuit Court of Appeals. The panel said administration officials must facilitate his return to the U.S. 'as soon as possible.' The judges gave them a week to identify his current physical location and custodial status and to specify what steps they will take to facilitate his return. Kilmar Abrego Garcia, whose mistaken deportation in March became a flashpoint in Trump's immigration crackdown, was returned from El Salvador this month to face human smuggling charges in Tennessee. In April, a Trump-nominated judge in Maryland ordered his administration to facilitate the return of a man who was deported to El Salvador in March despite having a pending asylum application. U.S. District Judge Stephanie Gallagher ruled that the government violated a 2019 settlement agreement when it deported the 20-year-old man, a Venezuelan native identified only as Cristian in court papers. And in May, another judge ordered the administration to facilitate the return of a Guatemalan man whom it deported to Mexico despite his fears of being harmed there. U.S. District Judge Brian Murphy found that the removal of the man, who is gay, likely 'lacked any semblance of due process.' Kunzelman writes for the Associated Press.
Yahoo
36 minutes ago
- Yahoo
China is a real threat to US biotech innovation: EY life science expert
China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts watching the deals flowing into China, which amounted $30 billion in 2024 and are already more than half that total in mid-2025. EY life sciences leader Arda Ural is among those watching and said that China is no longer the land of generics and active pharmaceutical ingredients (APIs) used by the rest of the world. China has long been known as a "me too" producer — that is, a manufacturer of generics — as well as a source of APIs. But China is showing its might as it clinches more licensing deals for drugs developed domestically and increases clinical trials being conducted in the country. "The numbers are pretty compelling," Ural told Yahoo Finance. "A couple of years ago, we had pretty much no deals, or maybe under $1 billion in 2016. As of last year, there were $30 billion of licensing deals of Chinese assets into the US." But this didn't happen overnight. The Chinese Communist Party laid out a roadmap in 2015 that included investing in and growing the country's biotech sector. Ten years later, that is coming to fruition, Ural said. "That journey now is taking them upstream to more advanced innovation. Probably, we still have not seen first-in-class, but clearly they are going for best-in-class," Ural said. US companies buying or licensing products from China include a due diligence process, which can involve head-to-head comparisons to existing drugs or repeating clinical trials to ensure the data and efficacy results are accurate. This has helped ease concerns about intellectual property theft of US products, as well as concerns about data integrity in China. The prior doubts spurred the introduction of the Biosecure Act in Congress in 2023, which would prevent any entity receiving federal funds from using biotech equipment or services from "companies of concern." That bill has stalled in Congress. Meanwhile, the life sciences community continues to increase its interest in China. Companies like WuXi Biologics (WXXWY), WuXi AppTec (WUXAY), and BGI (formerly Beijing Genomics Institute) are among those under the spotlight. And during the pandemic, companies like CanSino ( which developed a vaccine, came into view. Now, with cuts to research funding in the US to the National Institutes of Health (NIH), as well as the loss of Food and Drug Administration staff, insiders are warning that China could fill the gaps and scoop up talent from the US. "The US still has the capacity to invest, but it is not, potentially, the only game in town," Ural said. He explained that China is still early in its journey, and while it does have government funding and Western-educated doctors and researchers, it doesn't have the type of firepower of US capital markets. "That is where they are lacking. There is no IPO market comparable to Western markets, there is no M&A exit strategy ... so that's the opportunity for them to come up," Ural said. A majority of the deals so far are US-based companies buying early-stage assets from Chinese company pipelines, bringing them to the US to validate and then produce and sell. At the same time, the US-based biotech industry has seen a slowdown in investment and IPO activity, and the NIH funding cuts by the Trump administration are exacerbating the dry spell. China's growth is also adding to the pressure since China is known for making things cheaper and faster than Western countries. Ural said that's why the partnership with US-based firms is a "winning strategy" for the overall industry. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
New York Times
37 minutes ago
- New York Times
Trump Says He May Send Additional Patriot Systems to Ukraine
President Trump said Wednesday that he was weighing sending additional Patriot air defense systems to Ukraine amid intensifying Russian attacks. But it was not immediately clear whether Mr. Trump was considering donating the Patriots to Ukraine — as his predecessor, former President Joseph R. Biden Jr., and several European allies have done — or selling them to Kyiv. 'We're going to see if we can make some available,' Mr. Trump said during a news conference at the NATO summit in The Hague, where he held a nearly hourlong meeting with President Volodymyr Zelensky of Ukraine. But Mr. Trump cautioned that the systems, which Mr. Zelensky proposed buying directly in April, were 'very hard to get' and in limited supply, especially with the United States already providing some to Israel. Mr. Zelensky said in a statement that his meeting with Mr. Trump had been 'meaningful' and that the pair had discussed the prospects for a cease-fire. But neither he nor the White House offered details about how the meeting unfolded or whether it would lead additional American support. Mr. Zelensky has a complicated relationship with Mr. Trump, marked by meetings that have at times been tense and fraught, and at other times more substantive. His visit to the White House in February, where he was supposed to sign a landmark bilateral minerals deal, quickly unraveled as the two leaders publicly argued in the Oval Office. It took two more months for them to sit down together again, on the sidelines of Pope Francis' funeral in late April. That meeting helped defuse tensions between Kyiv and Washington and finalize the minerals deal. Want all of The Times? Subscribe.
